Epic Sciences gathers $52M for blood tests that match cancer patients to therapies

Red blood cells
The platform aims to predict individual patients’ responses to different cancer therapies by identify cancer cells in the bloodstream using computer vision and machine learning. (Wikimedia Commons)

Cancer blood test company Epic Sciences brought in $52 million to advance its suite of liquid biopsies, which use computer vision and machine learning to identify circulating tumor cells while characterizing the body’s immune response at the same time, toward regulatory approval.

The platform, dubbed No Cell Left Behind, aims to predict individual patients’ responses to different cancer therapies and combinations, as well as to detect early drug resistance. Epic also plans to use the new funds to help integrate its tests with electronic health records and big data analytics to establish patterns in cancer cell evolution, drug selection and clinical outcomes.

The series E round was led by Blue Ox Healthcare Partners, with participation from Deerfield Management and new partner Varian Medical Systems. Previous investors, including Altos Capital Partners, Genomic Health, Domain Associates, VI Ventures, Alexandria Venture Investments and Sabby Management, also returned to back the San Diego-based company.

WEBINAR

Accelerate Clinical Operations Across Sponsors, CROs and Partners With a Best-of-Breed Partner Like Box

Tuesday, March 24 | 11am ET / 8am PT

Learn how Box is a critical force multiplier in the Best-of-Breed application stack with partners like Nintex, DocuSign and Slack in supporting clinical operations for both regulated and non-regulated content.

"We are very excited to work with Epic in this emerging field of personalized medicine,” Renate Parry, Varian’s U.S. senior director of global translational science, said in a statement.

“The collaboration could lead to novel tests for stratifying patients receiving radiation therapy, and guide clinicians in the optimal ways to combine treatments such as immunotherapy and radiotherapy," Parry said.

RELATED: Epic Sciences nets $40M for cancer liquid biopsy

“Epic’s revolutionary diagnostics and decision support analytics optimize cancer treatment by ensuring each patient’s unique cancer cells get therapy that offers the highest likelihood of prolonged survival, while avoiding wasteful treatments that the patient’s individual cancer cells do not have the biology to respond to,” said Charles Kennedy, managing partner at Blue Ox, which plans to provide Epic management team support.

Earlier this year, Genomic Health began offering the Oncotype DX AR-V7 Nucleus Detect test, developed by Epic, as a predictive blood test that aims to pinpoint when a patient with castration-resistant metastatic prostate cancer needs to switch from targeted therapy to chemotherapy.

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.